CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Direct Acting Oral Anti-Coagulants for Venous Thromboembolism Prophylaxis after Partial Hip Replacement: Clinical Evidence and Guidelines

Last updated: May 11, 2018
Project Number: RB1220-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical evidence regarding the use of direct-acting anticoagulants for venous thromboembolism prophylaxis following partial hip replacement?
  2. What is the clinical evidence regarding the use of direct-acting anticoagulants for venous thromboembolism prophylaxis following hip fracture repair?
  3. What are the evidence-based guidelines regarding the use of direct-acting anticoagulants for venous thromboembolism prophylaxis following partial hip replacement or hip fracture repair?

Key Message

One systematic review with meta-analysis, three randomized controlled trials, and one non-randomized studies were identified regarding direct-acting oral anti-coagulants for venous thromboembolism prophylaxis after partial hip replacement.